Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles

Allémann, Éric; Rousseau, Jacques; Brasseur, Nicole; Kudrevich, Svetlana V.; Lewis, Karina; Lier, Johan E. van

doi:10.1002/(sici)1097-0215(19960611)66:6<821::aid-ijc19>3.0.co;2-5

Cited by 92 publications

(49 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The properties of PLGA (and related) nanoparticles can be further improved through PEGylation [117,118]. Such nanoparticles then have a core-shell structure with a PLGA core and a PEG coating.…”

Section: Biodegradable Nanoparticlesmentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has developed over last century and is now becoming a more widely used medical tool having gained regulatory approval for the treatment of various diseases such as cancer and macular degeneration. It is a two-step technique in which delivery of a photosensitizing drug is followed by irradiation of light. Activated photosensitizers transfer energy to molecular oxygen which results in generation of reactive oxygen species which in turn cause cells apoptosis or necrosis. Although this modality has significantly improved quality of life and survival time for many cancer patients it still offers significant potential for further improvement. In addition to the development of new PDT drugs, the use of nanosized carriers for photosensitizers is a promising approach which might improve the efficiency of photodynamic activity and which can overcome many side effects associated with classic photodynamic therapy. This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. PDT -photodynamic therapy; PGA -poly(glycolic acid); PGLA -poly(D,L-lactide-coglycolide); PLA -poly(lactic acid); PS -photosensitizer; PEG -polyethylene glycol; ALA  aminolevulinic acid; m-THPC  5,10,15,20-tetra-(m-hydroxyphenyl)chlorine; m-THPP  meso-tetra(p-hydroxyphenyl); PpIX  protoporphyrin; Hp  hematoporphyrin; Pc4  silicon phthalocyanine; Ig  immunoglobulin; Tf  transferrin; TfR  transferrin receptor; VEGF  vascular endothelial growth factor; EPR  enhanced permeability and retention effect; FRET  fluorescence resonance energy transfer; MRI  magnetic resonance imaging; RES  reticuloendothelial system; ROS  reactive oxygen species; NP  nanoparticle; ND -nanodiamonds; SNP  silica nanoparticle; AMD  age-related macular degeneration; CNV  choroidal neovascularization; PTT  photothermal therapy;

show abstract

Section: Biodegradable Nanoparticlesmentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

show abstract

“…12,13,48 Analogous events occur with PS administered as emulsions. 64 The use of other vehicles, such as microspheres 34 or nanoparticles, 65 enables the intracellular delivery of PS to phagolysosomes. The covalent attachment of the PS chlorin e6 to 1 µm polystyrene microspheres results in its entry into MGH-U1 human transitional cell bladder carcinoma cells via phagocytosis.…”

Section: Systems For Photosensitizer Delivery Into Cellsmentioning

confidence: 99%

Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency

Jans²,

2000

View full text Add to dashboard Cite

IntroductionPhotodynamic therapy (PDT) is a relatively new cytotoxic treatment, predominantly used in anticancer approaches, that depends on the retention of photosensitizers (PS) in tumour cells and their activation within the tumour through irradiation with light of the appropriate wavelength. Photoactivated PS generate reactive oxygen species (singlet oxygen, 1 O 2 , and free radicals, such as ·OH, HO· 2 and ·O 2 -) which are able to damage cellular structures, meaning that PDT is particularly attractive as an alternative means to kill drug-and radioresistant tumour cells.1,2 Normal cells, however, are also able to accumulate PS and be damaged by them, so that prolonged skin photosensitization, light-sensitivity of the eye and other side-effects have proved to be severe limitations of PDT. When photoactivated, PS inflict damage on many types of biomolecules without any specificity, their action being mediated largely via the reactive oxygen species mentioned, none of which travel more than several tens of nanometers before reacting with a biomolecule. Keeping in mind that cell dimensions are of the order of micrometres or tens of micrometres, it is clear that the intracellular action of PS is restricted to the site of their subcellular location and the surrounding radius of not more than 40 nm.3-5 That uneven intracellular distribution of PS can lead to differences in toxicity has been shown using laser microbeam irradiation. 6In contrast to cell membranes and other cytoplasmic organelles, the cell nucleus 7-9 is known to be a very sensitive target for reactive oxygen species. In order to reduce the dose of PS administered to patients and hence minimize the harmful side-effects of PDT, new approaches have been devised to increase the effectiveness of tumour-cell killing through targeted delivery of PS to hypersensitive subcellular sites. These approaches are the focus of the present review. Subcellular distribution of photosensitizersInsomuch as most mammalian cells span tens of micrometres, it is clear that PS efficiency will depend not only on the relative distribution of PS between the tumour and surrounding tissues and between malignant and normal cells, but also on the intracellular distribution of the PS. Furthermore, membranes divide the interior of the eucaryotic cell into compartments that differ markedly in their sensitivity to reactions induced by PS-generated reactive oxygen species, in the ability of damaged molecules to be replaced/recycled and in the extent to which such damage affects cell viability and/or the capability of the cell to divide. It is noteworthy that preferential PS accumulation in tumours is itself not a guarantee of selective photoinduced tumour damage and successful PDT. In experiments on rats with gliosarcoma 9L, 10 for example, it has been found that despite a 13-fold higher accumulation of the PS Photofrin in the tumour compared with Summary Photodynamic therapy (PDT) is a novel treatment, used mainly for anticancer therapy, that depends on the retention of photosensitizer...

show abstract

“…The fragility of the adsorbed coating and the large size (>900 nm) could be responsible for this failure. How-ever, formulation of the photosensitizer in the biodegradable nanospheres improved photodynamic therapy response, probably by influencing the intratumoral distribution pattern of the photosensitizer [35]. The biodistribution of non-biodegradable poly(methyl methacrylate) nanospheres coated or not with different surfactants (Polysorbate 80, Poloxamer 407 and Polaxamine 908) have been investigated in several mice bearing tumor models, including a murine B16-melanoma (inoculated intramuscularly), a human breast cancer MaTu (engrafted subcutaneously) and an U-373 glioblastoma (implanted intracerebrally).…”

Section: Sterically Stabilized Nanoparticlesmentioning

confidence: 99%

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

Serpe

2003

Nanotechnologies for the Life Sciences

View full text Add to dashboard Cite

The sections in this article are Introduction Cancer as Drug Delivery Target Nanoparticles as Anticancer Drug Delivery System Conventional Nanoparticles Sterically Stabilized Nanoparticles Actively Targetable Nanoparticles Routes of Drug Nanoparticles Administration Anticancer Drug Nanoparticles Anthracyclines Reverse of P‐glycoprotein Mediated Multidrug Resistance of Cancer Cells to Doxorubicin Antiestrogens Anti‐metabolites Camptothecins Cisplatin Paclitaxel Miscellaneous Agents Arsenic Trioxide Butyric Acid Cystatins Diethylenetriaminepentaacetic Acid Mitoxantrone Gene Therapy

show abstract

Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles

Cited by 92 publications

References 14 publications

Nanodrug applications in photodynamic therapy

Nanodrug applications in photodynamic therapy

Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency

Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment

Contact Info

Product

Resources

About